BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
344.11
-1.11 (-0.32%)
At close: 4:00PM EDT

344.11 0.00 (0.00%)
After hours: 7:17PM EDT

Stock chart is not supported by your current browser
Previous Close345.22
Open347.56
Bid330.00 x 1000
Ask351.88 x 1400
Day's Range341.79 - 347.56
52 Week Range249.17 - 388.67
Volume677,090
Avg. Volume1,816,923
Market Cap69.319B
Beta1.40
PE Ratio (TTM)24.43
EPS (TTM)14.08
Earnings DateOct 22, 2018 - Oct 26, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est389.31
Trade prices are not sourced from all markets
  • Examining Amgen’s Revenue Trend in Q2 2018
    Market Realist7 hours ago

    Examining Amgen’s Revenue Trend in Q2 2018

    As we discussed earlier, Amgen (AMGN) reported a 4% rise in its year-over-year revenue to ~$6.06 billion in the second quarter compared to $5.81 billion in the first quarter of 2017. Amgen surpassed analysts’ estimates for EPS and revenue in the second quarter, reporting non-GAAP (generally accepted accounting principles) EPS of $3.83 on revenue of ~$6.1 billion compared to the estimate of $3.54 on revenue of $5.7 billion.

  • A Look at Amgen’s Valuation on August 20
    Market Realist8 hours ago

    A Look at Amgen’s Valuation on August 20

    Amgen (AMGN) is a leading biotechnology company focused on discovering, developing, manufacturing, and delivering human therapeutics.

  • Spinraza Still a Key Asset for Biogen in 2018
    Market Realist14 hours ago

    Spinraza Still a Key Asset for Biogen in 2018

    In Q2 2018, Biogen’s (BIIB) SMA (spinal muscular atrophy) drug Spinraza reported global revenues of $423 million. Biogen is focused on increasing the adoption of Spinraza in the adult population by establishing adult treatment centers, creating awareness about the benefits of the therapy, and working to expand access to the drug. In Q2 2018, Spinraza saw a 20% sequential rise in the number of adult patients and a 10% sequential rise in the number of total patients in the United States.

  • Allergan’s US General Medicines Segment in Q2 2018
    Market Realist14 hours ago

    Allergan’s US General Medicines Segment in Q2 2018

    Allergan’s (AGN) US General Medicines segment includes women’s health products, central nervous system products, anti-infective products, gastrointestinal products, and diversified brands.

  • Tecfidera and Tysabri Still Driving Biogen’s Revenue Growth
    Market Realist15 hours ago

    Tecfidera and Tysabri Still Driving Biogen’s Revenue Growth

    Biogen expects to witness robust demand trends for Tecfidera in ex-US markets in 2018. In Q2 2018, Biogen’s Tecfidera reported revenues of ~$1.1 billion, a decline of 2% YoY (year-over-year) but a rise of 10% sequentially. Tecfidera also reported revenues of ~$261 million from the ROW (rest of world) markets, which is a rise of 11% YoY and a rise of 1% sequentially.

  • Allergan’s US Specialized Therapeutics Segment in Q2 2018
    Market Realist15 hours ago

    Allergan’s US Specialized Therapeutics Segment in Q2 2018

    Allergan’s (AGN) US Specialized Therapeutics segment includes revenue from the US sales of specialized products, including eye care products, medical esthetics products, dermatology products, neuroscience products, and urology products.

  • Biogen Expected to Report Robust Rise in Diluted EPS in 2018
    Market Realist3 days ago

    Biogen Expected to Report Robust Rise in Diluted EPS in 2018

    In its Q2 2018 earnings conference call, Biogen (BIIB) updated its 2018 GAAP EPS guidance from the previously projected range of $22.20–$23.20 to $21.80–$22.40, which implies a YoY (year-over-year) rise of 83%–87%.

  • Is Biogen (BIIB) Outperforming Other Medical Stocks This Year?
    Zacks3 days ago

    Is Biogen (BIIB) Outperforming Other Medical Stocks This Year?

    Is (BIIB) Outperforming Other Medical Stocks This Year?

  • Analyst Recommendations for Biogen and Its Peers in August
    Market Realist4 days ago

    Analyst Recommendations for Biogen and Its Peers in August

    On July 25, Biogen (BIIB) and Eisai announced positive results from the Phase 2 study evaluating BAN2401, an investigational anti-amyloid-beta (or Aβ) protofibril antibody, in early Alzheimer’s disease (or AD) indication after 18 months of therapy. The patients also included those suffering from AD-related mild cognitive impairment as well as those with mild AD. The results from the Phase 2 trial seem to validate beta-amyloid as a potential target for treating Alzheimer’s disease.

  • Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children
    Zacks5 days ago

    Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children

    Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years

  • Reuters6 days ago

    Express Scripts staking out million-dollar gene therapies

    Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs. Express Scripts is in talks with biotechnology companies Biomarin Pharmaceutical Inc (BMRN.O), Spark Therapeutics Inc (ONCE.O) and Bluebird Bio Inc (BLUE.O) to have its specialty pharmaceutical business exclusively distribute their new haemophilia therapies when they are expected to become available in 2019 and 2020, Chief Medical Officer Steve Miller told Reuters in an interview.

  • MarketWatch6 days ago

    Bridgewater adds Alibaba, Amazon, Baidu, keeps large gold holdings

    MARKET PULSE Hedge-fund giant Bridgewater Associates, with about $160 billion under management, has added 84,629 shares of Alibaba Group Holding Ltd. (baba) worth some $15.7 million, to its holdings, according to a regulatory filing on Tuesday.

  • Reuters7 days ago

    Biogen's pricey muscle drug Spinraza too costly for Britain

    Biogen's (BIIB.O) muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker. Spinraza, which has a U.S. list price of $750,000 in the first year of treatment, is a big money-spinner in Biogen's home market.

  • Reuters7 days ago

    Biogen's pricey muscle drug Spinraza too costly for Britain

    Biogen's muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker. Spinraza, which has a U.S. list price of $750,000 in the first year of treatment, is a big money-spinner in Biogen's home market.

  • There’s new evidence that the dominant approach to Alzheimer’s may be completely wrong
    MarketWatch8 days ago

    There’s new evidence that the dominant approach to Alzheimer’s may be completely wrong

    Experts are questioning a major scientific theory of the disease, which could mean two Biogen drugs won’t be successful.

  • Why Biogen's Stock Ripped Higher in July
    Motley Fool9 days ago

    Why Biogen's Stock Ripped Higher in July

    Biogen's stock got a boost from two material events last month.

  • Investopedia10 days ago

    4 Biotech Stocks That May Fall By as Much as 13%

    Biotech stocks have been hot since the beginning of May, rising by about 13% as measured by the iShares Nasdaq Biotechnology ETF ( IBB), more than double the pace of the S&P 500's rise. Shares of Intercept Pharmaceuticals Inc. ( ICPT) have risen by more than 63% since the beginning of May, while recently posting better-than-expected quarterly results that beat on both the top and bottom lines. The stock has run into a level of technical resistance around $118, posing as the first issue. Additionally, the relative strength index is showing signs that the stock is now overbought, rising above 70 three times since the start of June.

  • Biotech ETFs in Focus on String of Q2 Earnings Beat
    Zacks10 days ago

    Biotech ETFs in Focus on String of Q2 Earnings Beat

    Biotech ETFs draw attention post impressive Q2 results.

  • BeiGene’s Q2 2018 Earnings: Reports Revenue Growth
    Market Realist11 days ago

    BeiGene’s Q2 2018 Earnings: Reports Revenue Growth

    BeiGene (BGNE) released its second-quarter earnings on August 9. The company surpassed Wall Street analysts’ estimates for revenues but missed its EPS estimates. BeiGene reported adjusted EPS of -$2.92 on revenues of $52.8 million, compared to its estimated EPS of -$2.06 on revenues of $22.5 million. The chart below compares BeiGene’s revenues and EPS since the first quarter of 2017.

  • Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth
    Market Realist11 days ago

    Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth

    Sarepta Therapeutics (SRPT), a commercial-stage biopharmaceutical company, develops unique RNA-targeted therapeutics, gene therapies, and other medicines for neuromuscular diseases. It released its Q2 2018 earnings on August 8 and surpassed Wall Street analysts’ estimates for EPS and revenues. It reported adjusted EPS of -$0.43 on revenues of $73.5 million compared to the estimated EPS of -$0.89 on revenues of $71.6 million.

  • Ionis Pharmaceuticals (IONS) Q2 2018 Earnings Conference Call Transcript
    Motley Fool11 days ago

    Ionis Pharmaceuticals (IONS) Q2 2018 Earnings Conference Call Transcript

    IONS earnings call for the period ending June 30, 2018.

  • Morningstar12 days ago

    What Separates Primecap Odyssey Growth From the Rest?

    The following is our latest Fund Analyst Report for Primecap Odyssey Growth POGRX . Morningstar Premium Members have access to full analyst reports such as this for more than 1,000 of the largest and best mutual funds. Primecap Odyssey Growth is one of a select number of funds run by Primecap Management, whose fundamentals-based multimanager approach richly rewards long-term investors.

  • A Look at Ionis’s Revenue Streams in the Second Quarter
    Market Realist12 days ago

    A Look at Ionis’s Revenue Streams in the Second Quarter

    As discussed earlier, Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to revenues of $112 million during the second quarter of 2017. Ionis missed Wall Street analyst estimates for revenues and EPS in Q2 2018. Ionis reported commercial revenues of $57 million during Q2 2018, over 100% growth as compared to commercial revenues of $24 million during the second quarter of 2017.

  • See what the IHS Markit Score report has to say about Biogen Inc.
    Markit13 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    Biogen Inc NASDAQ/NGS:BIIB

  • Benzinga13 days ago

    Stifel Buys Back Into Biogen, Sees Upside In Alzheimer's Candidate

    The Street leans bullish on Biogen Inc (NASDAQ: BIIB ), and one sidelined analyst doesn’t want to miss on the profits. The Rating Stifel Nicolaus analyst Paul Matteis resumed coverage of Biogen with a ...